Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash & Equivalents (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Cash & Equivalents data on record, last reported at $868.2 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 771.74% year-over-year to $868.2 million; the TTM value through Dec 2025 reached $868.2 million, up 771.74%, while the annual FY2025 figure was $868.2 million, 771.74% up from the prior year.
  • Cash & Equivalents reached $868.2 million in Q4 2025 per VRDN's latest filing, up from $169.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $868.2 million in Q4 2025 and bottomed at $27.7 million in Q2 2021.
  • Average Cash & Equivalents over 5 years is $148.9 million, with a median of $105.2 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: plummeted 67.58% in 2023, then soared 771.74% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $42.3 million in 2021, then surged by 267.81% to $155.6 million in 2022, then plummeted by 33.91% to $102.8 million in 2023, then fell by 3.14% to $99.6 million in 2024, then skyrocketed by 771.74% to $868.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $868.2 million in Q4 2025, $169.6 million in Q3 2025, and $117.3 million in Q2 2025.